Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of immunotherapy (IO) with stereotactic body radiation therapy (SBRT) to IO alone in treating patients with liver cancer (hepatocellular cancer) that may have spread from where it first started to n…
Sponsor: NRG Oncology
NCT ID: NCT07166406
Locations: - Alta Bates Summit Medical Center-Herrick Campus — Berkeley, California
- Sutter Cancer Centers Radiation Oncology Services-Cameron Park — Cameron Park, California
- Palo Alto Medical Foundation-Fremont — Fremont, California
+ 104 more sites in the U.S.
Phase 3 Recruiting Industry
This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of rilvegostomig in combination with bevacizumab with or without tremelimumab compared to atezolizumab in comb…
Sponsor: AstraZeneca
NCT ID: NCT06921785
Locations: - Research Site — Phoenix, Arizona
- Research Site — Tucson, Arizona
- Research Site — Palo Alto, California
+ 29 more sites in the U.S.
Phase 3 Recruiting Industry
A Phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of paltusotine treatment vs placebo as well as the long-term safety of paltusotine in adults with carcinoid syndrome due to well-differenti…
Sponsor: Crinetics Pharmaceuticals Inc.
NCT ID: NCT07087054
Locations: - Banner MD Anderson Cancer Center — Gilbert, Arizona
- Hoag Memorial Hospital Presbyterian — Newport Beach, California
- Yale University - New Haven Hospital - Yale Cancer Center — New Haven, Connecticut
+ 13 more sites in the U.S.
Phase 2, Phase 3 Recruiting Industry
Hepatocellular carcinoma (HCC) is a common cancer worldwide and a leading cause of cancer-related death. The majority of participants first presenting with HCC have advanced unresectable or metastatic disease. The purpose of this study is …
Sponsor: AbbVie
NCT ID: NCT06109272
Locations: - City of Hope /ID# 261468 — Duarte, California
- City of Hope at Orange County Lennar Foundation Cancer Center /ID# 261669 — Irvine, California
- UC Irvine /ID# 255673 — Orange, California
+ 10 more sites in the U.S.
Phase 3 Recruiting Academic/Other
This study is a non-randomized, open-label, multi-cohort, multi-site, pilot feasibility therapeutic trial. The study will enroll 20 patients across 4 cohorts (CRC, gastric, PDAC, and HCC/intra-hepatic-/extra-hepatic-, gall bladder adenocar…
Sponsor: Georgetown University
NCT ID: NCT05482516
Locations: - Georgetown Lombardi Comprehensive Cancer Center — Washington D.C., District of Columbia
- Medstar Washington Hospital Center — Washington D.C., District of Columbia
- John Theurer Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey
Phase 2, Phase 3 Recruiting Academic/Other
This is a single-site prospective study to describe efficacy endpoints of single agent memantine in patients with unresectable, locally advanced, or metastatic HCC otherwise not deemed candidates for intensive systemic therapy. In addition…
Sponsor: Inova Health Care Services
NCT ID: NCT06007846
Locations: - Inova Schar Cancer Institute — Fairfax, Virginia
- Inova Health Care Service — Falls Church, Virginia
Phase 3 Recruiting Industry
This is a clinical trial in patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh Class B7 (CPB7) cirrhosis whose disease has progressed on at least 1st-line therapy. The trial will evaluate the efficacy and safety of namode…
Sponsor: Can-Fite BioPharma
NCT ID: NCT05201404
Phase 2 Recruiting Industry
The purpose of this study is to assess the safety of atezolizumab and bevacizumab, or atezolizumab alone, as first-line treatment in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC) with Child-p…
Sponsor: Genentech, Inc.
NCT ID: NCT06096779
Locations: - University of Arizona Cancer Center — Tucson, Arizona
- UC San Diego Moores Cancer Center — La Jolla, California
- University of Southern California-Keck School of Medicine -1975 Zonal Ave — Los Angeles, California
+ 57 more sites in the U.S.
Phase 2 Recruiting NIH
This phase II trial tests how well giving durvalumab with standard chemotherapy, gemcitabine and cisplatin, before surgery works in treating patients with high risk liver cancer (cholangiocarcinoma) that can be removed by surgery (resectab…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06050252
Locations: - UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
- Los Angeles General Medical Center — Los Angeles, California
- UC Irvine Health/Chao Family Comprehensive Cancer Center — Orange, California
+ 55 more sites in the U.S.
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Sponsor: DualityBio Inc.
NCT ID: NCT05150691
Locations: - Helios Clinical Research — Cerritos, California
- California Research Institute — Los Angeles, California
- Sharp Memorial Hospital — San Diego, California
+ 32 more sites in the U.S.
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.
Sponsor: DualityBio Inc.
NCT ID: NCT05914116
Locations: - Research Site 111 — Tucson, Arizona
- Research Site 125 — Los Angeles, California
- Research Site 133 — Los Angeles, California
+ 25 more sites in the U.S.
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors.
Sponsor: Parabilis Medicines, Inc.
NCT ID: NCT05919264
Locations: - Honor Health — Scottsdale, Arizona
- Arizona Cancer Center at University of Arizona — Tucson, Arizona
- Stanford Cancer Institute, Stanford University — Palo Alto, California
+ 21 more sites in the U.S.